TEL AVIV, Israel, June 17, 2021 /PRNewswire/ — CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma endotype.
Read more here.
Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://blog.ourcrowd.com/cytoreason-collaborates-with-sanofi-using-its-ai-technology-to-gain-better-understanding-of-disease-mechanisms/
